,24,25 Collectively, these data suggest that the combination of MTL-CEBPA and pembrolizumab can promote increased T cell infiltration, activity, and a reduction in myeloid cells with an immunosuppressive phenotype in the TME and periphery, key steps for promoting anti-tumor immunity.26 This evidence concerns the gene CEBPA and neoplasm.